Aims of the study: Retrospective studies investigating the use of percent free free-PSA for early detection of prostate cancer were limited for various reasons: by their use of long-term stored sera, poor mix of non-cancer to cancer cases and the use of only men with PSA values between 4.0 and 10.0 ngamL. This prospective study investigates the clinical utility of percent free-PSA and complexed-PSA for early detection of prostate cancer in 219 consecutive men presenting for prostate biopsy. Methods: Of 246 consecutive men who underwent ultrasound guided sextant biopsy of the prostate for PSA elevation andaor suspicious digital rectal exam, 219 men had serum total PSA levels between 2.0 and 20.0 ngamL and were included in this study. Serum total, free and complexed (PSA±ACT) were measured (Hybritech Inc.). Results: Pathologic examinations demonstrated that 72% and 28% of the biopsies were non-cancer and cancer respectively. The mean percent free-PSA was statistically different between the groups (cancer 14% AE 6.4 and non-cancer 18 AE 9%, P`0.001) and improved cancer detection. PSA±ACT provided only modest improvement in cancer detection over that of total PSA. Among this cohort of men, the optimal total PSA re¯ex range for percent free-PSA was 3.0 ± 7.0 ngamL (38% speci®city) with a percent free free-PSA cut-off of 20% (95% sensitivity) yet only affected 56% of the cases. Conclusions: PSA±ACT added very little additional value to the clinical utility of total PSA for early detection. Percent free free-PSA performed well for all re¯ex ranges. A sensitivity and speci®city of 95% and 20% respectively were obtained using a single cut-off of 25% for percent free-PSA for the group of men with total PSA values between 4.0 and 10.0 and correlated well with recently reported prospective analyses.
Introduction
Prostate speci®c antigen (PSA) is recognized as the best tumor marker for early detection of prostate cancer. 1, 2 There remains little controversy regarding the clinical utility of serum total PSA for early detection, staging and monitoring of men for prostate cancer. However, early detection algorithms among men with serum total PSA levels between 4.0 and 10.0 ngamL (The diagnostic Gray Zone) suggest transrectal ultrasound (TRUS) sextant biopsy of the prostate of all men within this group in an attempt to identify the 25% who will harbor malignancy. 3 Of the various modi®cations to the total PSA assay that have been introduced to aid in decision making for men within this Diagnostic Gray Zone, the recently introduced use of percent free-PSA has provided the best clinical value in distinguishing prostate cancer from benign prostatic conditions.
Contemporary thinking suggests that the use of percent free-PSA will increase the speci®city of PSA (decrease the number of unnecessary biopsies) while maintainingaimproving the sensitivity (number of positive biopsies detected among men who actually have cancer) as close to 100% as possible. Previous retrospective studies have reported percent free-PSA cut-off values ranging from 14 ± 25% that have maintained sensitivity ranging from 90 ± 100% and increased the speci®city of the test ranging from 20 ± 40%. 4 ± 11 The variability between data presented from those retrospective studies is most likely related to study design, retrospective sample analysis, poor non-cancer vs cancer mix of subjects and the use of long-term stored archival sera. In addition, previous attempts to measure complexed PSA (PSA±ACT: PSA bound to a-1-antichymotrypsin) have been limited to the high cross reactivity of the monoclonal antibodies to other ACT bound serum proteins such as cathepsin-G (Abstract, Daniel W. Chan et al. Clin Chem 42: S255, 1996). Hybritech Inc. has recently developed a PSA±ACT speci®c assay with little cross reactivity with other proteins. 12 In this study, we enrolled consecutive men into a prospective multi-institutional study to determine the clinical utility of total PSA, free-PSA, PSA±ACT, percent free-PSA and various combinations of these assays for early detection of prostate cancer.
Materials and methods

Study design
Sera were obtained in a prospective fashion from consecutive men enrolled in a prospective prostate cancer early detection research study performed at two University Medical Centers between June 1995 and June 1996. Sera were obtained prior to prostatic biopsy and long enough after prostatic manipulation (DRE) not to alter PSA levels. Patient enrollment criteria was determined by the need for TRUS sextant biopsy of the prostate for an elevation in total PSA (b 4.0 ngamL, Hybritech Inc) andaor a suspicious digital rectal examination. No man reported taking ®nasteride prior to enrollment into this study. During this enrollment, 246 consecutive men underwent TRUS guided sextant biopsy of the prostate at these two institutions. All blood samples were centrifuged and the sera removed from the clot in a standard fashion within 3 h of phlebotomy. Samples were then immediately stored at 770 C until batch analysis at the end of the study (range 1±12 months). Total PSA levels were determined using the Hybritech Tandem-R PSA monoclonal antibody assay. Free-PSA concentrations were determined using a research prototype of the Hybritech Tandem-R free-PSA assay, a dual monoclonal antibody immunoassay for the free molecular form of PSA. The complexed form of PSA (PSA±ACT) was measured using a research prototype of the Hybritech Tandem microtiter plate assay. All analyses were performed in one laboratory at The Johns Hopkins Hospital.
Twenty-seven subjects were not included in this study secondary to total serum PSA levels either below 2.0 ngamL or total serum PSA levels b 20.0 ngamL. The remaining 219 subjects constituted the study group for this analysis. Only subjects without prior history of prostate biopsy were included in this analysis.
Pathological analysis (performed at either The Johns Hopkins Hospital or The Seattle Veterans Affairs Medical Center) of sextant biopsy specimens were de®ned as a histological diagnosis of adenocarcinoma or non-cancer which included the diagnoses of benign prostatic diseases such as benign prostatic hyperplasia, normal prostate tissue, chronic in¯ammationaprostatitis, andaor histologically benign.
Statistical analysis
Percent free-PSA and other combinations of the assays were calculated as the ratio of two assays multiplied by 100 to yield a percent value. Intersite variability comparing patient demographics was tested using students t-test. A nonparameteric test (Wilcoxon) was utilized for comparisons between cancer and non-cancer groups with respect to the various individual assays as well as the combination of assays.
Receiver operating characteristic (ROC) curves were generated plotting true positive results (sensitivity) vs false positive results (1-speci®city). The area under the ROC curve was utilized only for general comparison between the clinical utility of the various assays. Assay performance was determined for various cut points that maintained a sensitivity of greater than 95%. The number of unnecessary biopsies spared (speci®city) was used to determine the optimal reference range for total PSA for the various assays. All statistical analyses were determined through the use of a statistics and graphics management system (STATA, Santa Monica, CA). Recursive partitioning was used to determine the optimal re¯ex range for the assays.
Results
Subject demographics
A total of 246 consecutive men underwent TRUS guided sextant biopsy of the prostate for an elevation of total PSA (b 4.0 ngamL) andaor an abnormal or suspicious DRE. Initial study enrollment criteria for this study protocol included only men with initial prebiopsy PSA levels between 2.0 and 20 ngamL. Three men with PSA levels greater than 20.0 ngamL (mean 25.7 AE 7.1, range 20.3±33.8) and 24 men with PSA levels less than 2.0 (mean 1.2 AE 0.52, range 0.19±1.97) were not included in the ®nal analysis. Table 1 outlines the demographics of the remaining 219 subjects in this study. Of the enrolled study subjects , 157 (72%) demonstrated no histological evidence of adenocarcinoma on sextant biopsy. The remaining 62 subjects (28%) demonstrated adenocarcinoma on at least one sextant biopsy core. In addition, there was no statistically signi®cant difference between the ratio of non-cancer to cancer subjects between sites. Likewise, the average age and number of men with suspicious digital rectal exams were not signi®cantly different between the two sites. In addition, there were no statistically signi®cant differences between the distri-bution of race between the sites. A single factor, the mean total PSA level at presentation, was statistically signi®cant (P`0.05) between sites with a higher value reported for those men biopsied at the Johns Hopkins Hospital. Lacking major intersite variability, all subjects were combined for subsequent analyses. Table 2 shows the mean and standard deviation of total PSA, free-PSA and PSA±ACT for subjects with cancer and those without histologic evidence of cancer on biopsy. There was a statistically signi®cant difference between groups when comparing both total PSA (P`0.05) and PSA±ACT (P`0.05). Free-PSA levels were not statistically different between the cancer and non-cancer groups. Table 3 demonstrates the differences between the noncancer and cancer groups for the various combinations of serum total PSA, free-PSA and PSA±ACT levels for the study group. Percent free-PSA provided the most statistically signi®cant separation between the two groups (P`0.001). Likewise, the percentage of the ratio of free-PSA over PSA±ACT was statistically signi®cant as well (P 0.002). The ratio of PSA±ACT over total PSA was not statistically different. As reported in previous studies, the percent free-PSA for subjects whose biopsies demonstrated adenocarcinoma was lower than the percent free-PSA for subjects who did not demonstrate cancer on their biopsy.
Receiver operating characteristic curves 3.0 ngamL provided similar sensitivity and speci®city to the cut-off of 4.0 for a total PSA. Interestingly, a PSA±ACT cut-off of 2.0 ngamL provided a sensitivity and speci®city of 90% and 23% respectively for detecting cancer. As a single test, when analyzed by ROC analysis, free-PSA provided very little predictive value (area under ROC curve approximately equal to 0.5) for detecting prostate cancer among this group of patients. Figure 2 demonstrates the receiver operating characteristic curves comparing the ratios of percent free-PSA, percent free-PASaPSA±ACT and percent complexed PSA (PSA±ACTaTotal PSA). The area under the ROC curve for percent free-PSA, percent free-PSAaPSA±ACT and percent complexed PSA were 0.63, 0.63 and 0.55 respectively. The ratios, percent free-PSA and percent free-PSAaPSA±ACT were better predictors of cancer among this population when comparing the area under the ROC curve. The percentage of complexed PSA (PSA±ACTaTotal PSA) provided little bene®t to prostate cancer detection among this group. Since, percent free-PSA demonstrated modestly better separation of the patients with respect to speci®city (elimination of unnecessary biopsies, while maintaining a sensitivity of b95%) detection of cancer. Further statistical analyses were performed to select the optimal cut-off and re¯ex range for percent free-PSA.
Optimal re¯ex range for use of percent free-PSA Table 4 demonstrates the distribution of non-cancer to cancer subjects, area under the ROC curve, speci®city (number of unnecessary biopsies spared), and the percent free-PSA cut-off used for various total PSA reference ranges. For these analyses, sensitivity was held to b95%. For the group as a whole (N 219), using a cutoff of 26% for percent free-PSA 18% of the unnecessary biopsies would have been spared. The optimal re¯ex range within this group of patients was a total PSA Figure 1 Receiver operating characteristic curves demonstrating the sensitivity and speci®city of total PSA (A), free-PSA (B) and complexed PSA (PSA±ACT) (C) for detection of prostate cancer for a group of 219 men. Arrows point to various total PSA levels (A) and complexed-PSA levels (C). The area under the ROC curves was 0.61, 0.53 and 0.63 for A, B and C respectively. and would have spared 38% of the unnecessary biopsies with a percent free-PSA cut-off of 20%. This total PSA re¯ex range (3.0±7.0 ngamL) would make this test useful for only 56% of the patients in this cohort. Other prospective studies 13 have recently reported a speci®city of 20% while maintaining a sensitivity of b95% using a cutoff of 25% for percent free-PSA for men with total PSA levels between 4.0 and 10.0 ngamL. As can be seen in Table 4 , our prospective study correlates well with Catalona's data which investigated the same assay.
Discussion
Men participating in an early detection program for prostate carcinoma with palpably normal prostates who present with a serum total PSA value between 4.0 and 10.0 ngamL, harbor a chance of detecting prostate cancer by transrectal ultrasound guided sextant biopsy between 25% and 30%. 14 The poor speci®city of the total PSA assay within this range is primarily due to the contribution of the BPH tissue within the prostate. The limited value of the total PSA test and our ability to estimate the contribution of BPH to total serum PSA levels has led to the recommendation that all men with PSA values within this range undergo biopsy of the prostate. This uncertainty prompts many men to undergo unnecessary prostatic biopsies to maintain an acceptable sensitivity for detecting prostate cancer for this group of men. Attempts to lessen this unacceptably high level of unnecessary biopsies have led many investigators to search for better means to enhance the use of PSA for cancer detection.
Of the various modi®cations to the total PSA assay that have been introduced to aid in decision making for men within the Diagnostic Gray Zone (4.0±10.0 ngamL), the recently introduced use of percent free-PSA has provided the best clinical value in distinguishing prostate cancer from benign prostatic conditions. 4±8, 13 There now exists strong evidence that the fraction of PSA bound to a-1 antichymotrypsin (PSA±ACT) may be higher in men with prostate cancer compared to the fraction measured in men with only BPH. 5±8 The physiologic basis of this difference is presently unknown.
Clinical trials designed to investigate the usefulness of percent free-PSA have attempted to increase the speci®city of the assay (decrease the number of unnecessary biopsies) while maintaining an acceptable sensitivity (as close to 100% as possible). Previous retrospective studies have reported percent free-PSA cut off values ranging from 14 ± 25% that have allowed sensitivities ranging from 90 ± 100% while increasing the speci®city of the assay between 20% and 40%.
4±11, 13 The marked variability between the results presented from these retrospective studies is most likely related to differences in study design, retrospective sample analysis, poor non-cancer to cancer mix of subjects and the use of long-term stored archival sera. The present study was designed to investigate in a prospective multi-institutional fashion the clinical utility of total PSA, free-PSA, PSA±ACT, percent free-PSA and the various combinations of these assays for early detection of prostate cancer among a group of men presenting for prostate biopsy for either a PSA elevation or an abnormal digital rectal exam ®nding.
This prospective multi-institutional study examined 219 men with serum total PSA levels between 2.0 and 20.0 ngamL all with histologically con®rmed diagnoses. Our results con®rmed earlier studies 5±8 in that percent free-PSA enhanced speci®city for prostate cancer detection over that seen by total PSA alone. In this study, unlike previous retrospective studies, consecutive men undergoing ultrasound guided sextant biopsy of the prostate were examined in a prospective fashion. Consequently, the case mix of non-cancer (72%) and cancer (28%) cases adequately represented those seen in standard urologic practice. There was a statistically signi®cant difference between the percent free-PSA seen between the cancer (14%) and non-cancer (18%) groups which improved cancer detection. PSA±ACT provided modest improvement in cancer detection over that seen by total PSA among this cohort of men. The optimal re¯ex range for use of percent free-PSA for this group of men was 3.0± 7.0 ngamL where this assay demonstrated a 95% sensitivity and a 38% speci®city utilizing a cut-off of 20% for percent free-PSA. Unfortunately, this optimal re¯ex range affected only 56% of the cases. Percent free-PSA performed with a sensitivity and speci®city of 95% and 20% respectively using a single cut-off of 25% for percent free-PSA for the group of men in the`Diagnostic Gray Zone' (PSA values between 4.0 and 10.0 ngamL). This result correlated well with a previous reported prospective analysis. 13 Our investigation of the various combinations of serum total PSA, free-PSA and PSA±ACT levels for this cohort of men demonstrated that percent free-PSA (free-PSA divided by total PSA) performed better than percent PSA±ACT (PSA±ACT divided by total PSA) or percent free-PSA to ACT (free-PSAaPSA±ACT). ROC analysis demonstrated comparable results between percent free-PSA and percent free-PSAaPSA±ACT (ROC±AUC 0.63 and 0.63 respectively). These data suggest a possible clinical role for further characterization of the PSA±ACT molecular form of PSA to enhance the clinical value of the test for early detection algorithms. Previous studies have suggested the optimal use of percent free-PSA might be dictated by total PSA levels. 7 Earlier studies suggested that the optimal percent free-PSA cut-off should decrease as total PSA increases and increase with increasing prostate volume and the volume of BPH within the gland. While these subcategorizations of total PSA, for example 4.0 ± 6.0 ngamL and 6.0 ± 8.0 ngamL, etc, do provide increased speci®city for the assay, the con®dence intervals surrounding these statistical analyses are limited secondary to the small number of patients within these subcategories of total PSA in these studies. As an example we demonstrated the optimal total PSA range for use of percent free-PSA was between 3.0 and 7.0 ngamL with a reported speci®city of 38% (elimination of unnecessary biopsies) using a cutoff value of 20% for percent free-PSA. This value however would have only been useful for 56% (122 out of 219) of the men involved in this study. Likewise, a recent prospective trial performed by Hybritech Inc. demonstrated that, with a ®xed sensitivity (90%), as total PSA rises from 2.6 ngamL to 10 ngamL the optimal percent free-PSA cutoff decreases from 27% for men with PSAs between 2.6 and 4 to an optimal percent free-PSA cut-off of 21% for men with total PSAs between 6 and 10 while the speci®city of the assay increased. 13 The present study con®rms these results. We, however, agree with the investigators in the Hybritech multi-institutional study in that selection of a single cut-off value (25% free-PSA) for the entire total PSA range between 4.0 and 10.0 would provide the simplest method for use of percent free-PSA and allow it to be useful for a larger proportion of patients undergoing early detection studies. If one chooses to select a high cutoff for percent free-PSA for men with lower total PSA values, one can expect a decrease in the speci®city obtained from the assay.
Limitations to this present study include the use of data obtained from men with suspicious digital rectal exams. Previous studies concluded that analysis of percent free-PSA for clinical utility should only include men with normal digital rectal exams. 5 These authors felt that data collected from men with suspicious digital rectal exams could not be applied directly since men with suspicious ®ndings on rectal exam are advised to undergo biopsy regardless of PSA or percent free-PSA levels. We recognize this as a limitation to this study, however, no data has presently been published demonstrating the lack of utility of percent free-PSA among men with suspicious digital rectal exams. Within this study, among the group of men with total PSA values between 2.0 and 20.0 ngamL, the area under the percent free-ROC curve for men with normal digital rectal exams was 0.59 compared to 0.64 for those with abnormal digital rectal exams. While this data in itself cannot be used to suggest that the presence or absence of a palpable lesion can in¯uence the performance of percent free-PSA for early detection, it does in fact demonstrate that use of men with positive digital rectal exam ®nding does not signi®cantly in¯uence the outcome of these study results. Another potential limitation to this prospective analysis involves the short term storage of samples (less than one year) until batch analysis could be performed. Woodrum et al 15 have recently demonstrated that routine serum preparation and refrigerated storage of samples of up to 24 h provided acceptable measurement of both free and total PSA and should not signi®cantly alter the use of percent free-PSA in clinical studies. They also demonstrated that storage of sera at 770 C for extended periods of time demonstrated a decrease of free-PSA of only 0.4% per month of storage at 770 C. Therefore, we do not feel as though the relatively short storage time for this study should have greatly affected the results. A ®nal limitation to this study relates to the fact that the results presented are applicable only to the clinical assay used in the study. The Hybritech Tandem free and total PSA assays were used for these studies and the data presented within this work refer only to assays performed by these techniques. Several recent studies have demonstrated that cut-off and clinical performance for percent free-PSA greatly differ when various combinations of free and total PSA assays are compared from different manufacturers. 16 ± 18 Therefore, the recommendations for use of percent free-PSA as outlined in this work apply only to the assays used in this study.
Conclusions
This prospective multi-institutional study of 219 consecutive men with total PSA levels between 2.0 and 20.0 ngamL who underwent biopsy as part of an early detection program for prostate cancer demonstrated that: (1) PSA±ACT provided only minor additional clinical value to the clinical utility of total PSA for early detection; (2) Of the various combinations of assays, percent free-PSA performed the best for all re¯ex ranges; (3) While the optimal re¯ex range of total PSA for the clinical utility of percent free-PSA among this cohort of men was 3.0±7.0 ngamL, this re¯ex range would only have affected 56% of the cases; (4) A single cut-0ff of 25% percent free-PSA demonstrated a speci®city of 95% and would have led to elimination of 20% of the unnecessary biopsies for men with total PSA values between 4.0 and 10.0 ngamL which correlated well with previously reported prospective analyses. These data con®rm in a prospective fashion that the use of percent free-PSA can in fact reduce the number of unnecessary biopsies in men with PSA levels between 4.0 and 10.0 ngamL with maintenance of clinically useful sensitivity. This study taken in combination with the recent report of the Hybritech Inc. prospective multi-institutional clinical trial provide sound statistical and clinical information supporting the use of percent free-PSA in early detection algorithms for men with PSA levels between 4.0 and 10.0 ngamL.
